Glenmark Pharmaceuticals Ltd, a research-led global pharmaceutical company, today announced that it has entered into an agreement with Hindustan Unilever Limited (HUL) for divestment of its VWash brand and other extensions. Under this agreement, the brand and other trademarks, copyrights, know-how associated with Glenmark's VWash business will be transferred to HUL. Glenmark will receive an upfront payment and royalty on sales for 3 years. No employees will be transferred as a part of this agreement. The transaction is expected to be completed in the next few months subject to customary approvals.
Glenmark launched VWash, a liquid vaginal wash, as an OTC product in 2013. The company continued to invest in building the brand and established it as a market leader in the intimate hygiene category. Over the years, Glenmark launched multiple line extensions like VWash Wipes to expand the brand offering across different consumer needs.
"The decision to divest VWash brand is driven by the strategy to focus on our core therapy areas. While Glenmark has been able to establish VWash as a category leader, we are confident that HUL'sstrong market presence and large distribution network will accelerate future growth of VWash." said Sujesh Vasudevan, President India Formulations, Middle East and Africa at Glenmark.
Glenmark intends to further consolidate its position in the core therapy areas of respiratory, dermatology and oncology globally. Glenmark's OTC business will focus on its other leading brands like Candid Powder, Scalpe and introduce new Rx to OTC switches.
Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.188 as compared to the previous close of Rs. 210.5. The total number of shares traded during the day was 157480 in over 4919 trades.
The stock hit an intraday high of Rs. 214.85 and intraday low of 184. The net turnover during the day was Rs. 30188925.